This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2014 Aug 1;32(22):2287-9.

doi: 10.1200/JCO.2014.56.3387. Epub 2014 Jun 23.

Irinotecan pharmacogenetics: a finished puzzle?

Mitch A Phelps¹, Alex Sparreboom²

Affiliations

Affiliations

¹ College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
² St Jude Children's Research Hospital, Memphis, TN alex.sparreboom@stjude.org.

PMID: 24958823
DOI: 10.1200/JCO.2014.56.3387

Editorial

Irinotecan pharmacogenetics: a finished puzzle?

Mitch A Phelps et al. J Clin Oncol. 2014.

. 2014 Aug 1;32(22):2287-9.

doi: 10.1200/JCO.2014.56.3387. Epub 2014 Jun 23.

Authors

Mitch A Phelps¹, Alex Sparreboom²

Affiliations

¹ College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH.
² St Jude Children's Research Hospital, Memphis, TN alex.sparreboom@stjude.org.

PMID: 24958823
DOI: 10.1200/JCO.2014.56.3387

No abstract available

PubMed Disclaimer

Comment on

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ. Innocenti F, et al. J Clin Oncol. 2014 Aug 1;32(22):2328-34. doi: 10.1200/JCO.2014.55.2307. Epub 2014 Jun 23. J Clin Oncol. 2014. PMID: 24958824 Free PMC article. Clinical Trial.

Similar articles

Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Nagar S, Blanchard RL. Nagar S, et al. Drug Metab Rev. 2006;38(3):393-409. doi: 10.1080/03602530600739835. Drug Metab Rev. 2006. PMID: 16877259 Review.
Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y, Ando Y, Ando M, Hashimoto N, Imaizumi K, Shimokata K. Hasegawa Y, et al. Ann N Y Acad Sci. 2006 Nov;1086:223-32. doi: 10.1196/annals.1377.020. Ann N Y Acad Sci. 2006. PMID: 17185519 Review.
Pharmacokinetics of irinotecan and its metabolites.
Siderov J. Siderov J. J Clin Oncol. 2002 Dec 1;20(23):4609; author reply 4609-10. doi: 10.1200/JCO.2002.99.190. J Clin Oncol. 2002. PMID: 12454126 No abstract available.
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY, Chen LT. Chang TC, et al. Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86. doi: 10.1007/s00280-014-2671-x. Epub 2015 Jan 11. Cancer Chemother Pharmacol. 2015. PMID: 25577133 Free PMC article. Clinical Trial.
Pharmacogenomics of tamoxifen and irinotecan therapies.
Algeciras-Schimnich A, O'Kane DJ, Snozek CL. Algeciras-Schimnich A, et al. Clin Lab Med. 2008 Dec;28(4):553-67. doi: 10.1016/j.cll.2008.05.004. Clin Lab Med. 2008. PMID: 19059062 Review.

See all similar articles

Cited by

Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer.
Rahman FAU, Ali S, Saif MW. Rahman FAU, et al. Therap Adv Gastroenterol. 2017 Jul;10(7):563-572. doi: 10.1177/1756283X17705328. Epub 2017 Apr 26. Therap Adv Gastroenterol. 2017. PMID: 28804517 Free PMC article. Review.
Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Campbell JM, Stephenson MD, Bateman E, Peters MD, Keefe DM, Bowen JM. Campbell JM, et al. Pharmacogenomics J. 2017 Jan;17(1):21-28. doi: 10.1038/tpj.2016.58. Epub 2016 Aug 9. Pharmacogenomics J. 2017. PMID: 27503581
Different schedules of irinotecan administration: A meta-analysis.
Shao Y, Lv H, Zhong DS. Shao Y, et al. Mol Clin Oncol. 2016 Aug;5(2):361-366. doi: 10.3892/mco.2016.920. Epub 2016 Jun 3. Mol Clin Oncol. 2016. PMID: 27446580 Free PMC article.
Treatment mechanism of matrine in combination with irinotecan for colon cancer.
Duan L, Deng L, Wang D, Ma S, Li C, Zhao D. Duan L, et al. Oncol Lett. 2017 Aug;14(2):2300-2304. doi: 10.3892/ol.2017.6407. Epub 2017 Jun 19. Oncol Lett. 2017. PMID: 28781667 Free PMC article.
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, Kroetz DL. Li M, et al. Pharmacogenomics J. 2018 Jan;18(1):35-42. doi: 10.1038/tpj.2016.75. Epub 2016 Nov 15. Pharmacogenomics J. 2018. PMID: 27845419 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations